



INSTITUT PAOLI-CALMETTES

Centre régional de lutte contre le cancer Provence-Alpes-Côte d'Azur



EBMT

European Society
for Blood and Marrow Transplantation

4TH INTERNATIONAL SYMPOSIUM

ADVANCES IN ALLOGENEIC IMMUNOTHERAPY: WHERE DO WE STAND IN 2018?

APRIL
20, 21 & 22
2018

**PALAIS DU PHARO
MARSEILLE, FRANCE**



FINAL PROGRAM

FACULTIES

Huisheng Ai,
Beijing, China
Borje Andersson,
Houston, USA
Andrea Bacigalupo,
Roma, Italy
Jacques-Olivier Bay,
Clermont-Ferrand, France
Ali Bazarbachi,
Beirut, Lebanon
Didier Blaise,
Marseille, France
Jaap Boelens,
Utrecht, The Netherlands
Attilio Bondanza,
Milan, Italy
Eolia Brissot,
Paris, France
Boris Calmels,
Marseille, France
Luca Castagna,
Milan, Italy
Stefan Ciurea,
Houston, USA
Raynier Devillier,
Marseille, France
Catherine Faucher,
Marseille, France
Ephraim Fuchs,
Baltimore, USA
Sabine Fürst,
Marseille, France
Raul Gabus,
Montevideo, Uruguay
Ivana Gojo,
Baltimore, USA
Angela Granata,
Marseille, France
Samia Harbi,
Marseille, France
Suradej Hongeng,
Bangkok, Thailand
Jiong Hu,
Shanghai, China
He Huang,
Hangzhou, China

Xiao Jun Huang,
Beijing, China
Surapol Issaragrisil,
Bangkok, Thailand
Fatemeh Izadifar-Legrand,
Marseille, France
Jong Wook Lee,
Seoul, South Korea
Claude Lemarié,
Marseille, France
Leo Luznik,
Baltimore, USA
Florent Malard,
Paris, France
Domenico Mavilio,
Milan, Italy
Mohamad Mohty,
Paris, France
Arnon Nagler,
Tel Hashomer, Israel
Stéphanie Nguyen-Quoc,
Paris, France
Daniel Olive,
Marseille, France
Simrit Parmar,
Houston, USA
Régis Peffault de Latour,
Paris, France
Finn Petersen,
Boise, USA
Marie-Thérèse Rubio,
Paris, France
Bipin Savani,
Nashville, USA
Jan Storek,
Calagry, Canada
Luca Vago,
Milan, Italy
Norbert Vey,
Marseille, France
Pierre-Jean Weiller,
Marseille, France
Ibrahim Yakoub-Agha,
Lille, France

4TH INTERNATIONAL SYMPOSIUM

ADVANCES IN ALLOGENEIC IMMUNOTHERAPY: WHERE DO WE STAND IN 2018?

APRIL
20, 21 & 22
2018

PALAIS DU PHARO
MARSEILLE, FRANCE

FRIDAY, APRIL 20TH, 2018

13.00	OPENING SESSION
13.30	SESSION 1 – IMMUNOLOGY
	<i>Chairs: Leo Luznik, Baltimore, USA & Stéphanie Nguyen-Quoc, Paris, France</i>
13.30	Monoclonal antibodies: what's next? Daniel Olive , Marseille, France
14.00	Update on the role of B cells in allo-HCT. Florent Malard , Paris, France
14.30	Immune reconstitution after Haplo HSCT. Domenico Mavilio , Milan, Italy
15.00	Discussion
15.15	SESSION 2 – ATG REVISITED
	<i>Chairs: Xiao Jung Huang, Beijing, China & Pierre-Jean Weiller, Marseille, France</i>
15.15	Towards predictable immune reconstitution after HCT for optimal survival chances. Jaap Boelens , Utrecht, The Netherlands
15.45	Dissociative identity (split personality) disorder of ATG, Jan Storek , Calgary, Canada
16.15	Discussion
16.30	<i>Coffee break & exhibition visit</i>
17.00	SESSION 3 – CAR-T CELLS... AND OTHERS?
	<i>Chairs: Didier Blaise, Marseille, France, Eolia Brissot, Paris, France & Boris Calmels, Marseille, France,</i>
17.00	Car-T cells: where are we in 2018? Attilio Bondanza , Milan, Italy
17.30	Car-T cells post allo HSCT. He Huang , Hangzhou, China
18.00	Treg adoptive immunotherapy. Simrit Parmar , Houston, USA
18.30	Novel allogeneic cell therapies of cancer. Ephraim Fuchs , Baltimore, USA
19.00	Discussion

FINAL PROGRAM

SATURDAY, APRIL 21ST, 2018

08.30 SESSION 4 – AML AND MDS

*Chairs: Samia Harbi, Marseille, France
& Mohamad Mohty, Paris, France*

08.30 The place of Haplo HSCT for AL in Europe:
what are the trends? **Arnon Nagler**, Tel Hashomer, Israel

09.00 Familial or HLA matched HSCT for AML?
Xiao Jun Huang, Beijing, China

09.30 Secondary Leukemia and haplo -SCT.
Bipin Savani, Nashville, USA

10.00 Haplo for MDS. **Ibrahim Yakoub-Agha**, Lille, France

10.30 Discussion

10.45 *Coffee break & exhibition visit*

11.15 SESSION 5 – RELAPSED/REFRACTORY AML

*Chairs: Raynier Devillier, Marseille, France
& Ivana Gojo, Baltimore, USA*

11.15 Loss of mismatched HLA in leukemia
after stem-cell transplantation. **Luca Vago**, Milan, Italy

11.45 Is treating refractory leukemia with allo HSCT appealing?
The leukemia doctor perspective. **Norbert Vey**, Marseille, France

12.15 How to choose a haplo donor:
impact of disease status? **Stefan Ciurea**, Houston, USA

12.45 *Lunch*

4TH INTERNATIONAL SYMPOSIUM

ADVANCES IN ALLOGENEIC IMMUNOTHERAPY: WHERE DO WE STAND IN 2018?

APRIL
20, 21 & 22
2018

PALAIS DU PHARO
MARSEILLE, FRANCE

14.00 SESSION 6 – LYMPHOMAS

*Chairs: Angela Granata, Marseille, France
& Marie-Thérèse Rubio, Paris, France*

14.00 Familial or HLA matched HSCT for lymphoma?
Luca Castagna, Milan, Italy

14.30 Prophylaxis of NHL relapse after transplant:
what are the tools? **Ali Bazarbachi**, Beirut, Lebanon

15.00 Discussion

15.15 SESSION 7 – NEW STRATEGIES TO IMPROVE RESULTS OF ALLOGENEIC TRANSPLANTS

*Chairs: Catherine Faucher, Marseille, France
& Florent Malard, Paris, France*

15.15 Post transplant Cy for HLA matched and mismatched
transplant: anything new? **Leo Luznik**, Baltimore, USA

15.45 Pre-transplant pharmacologic approach in non malignant
and malignant diseases. **Borje Andersson**, Houston, USA

16.15 Discussion

16.30 *Coffee break & exhibition visit*

17.00 SESSION 8 – TOXICITIES IN TRANSPLANT AND IMMUNOTHERAPIES

*Chairs: Raul Gabus, Montevideo, Uruguay
& Surapol Issaragrisil, Bangkok, Thailand*

17.00 Haplo-ID transplant related complications: what we know,
and what we need to learn. **Finn Petersen**, Boise, USA

17.30 Toxicities of Car-T cells. **Mohamad Mohty**, Paris, France

18.00 How to deal with older age in allo HSCT.
Didier Blaise, Marseille, France

18.30 Discussion

20.30 *Congress Dinner*

FINAL PROGRAM

SUNDAY, APRIL 22ND, 2018

08.30 SESSION 9 – NON MALIGNANT DISEASES

*Chairs: Régis Peffault de Latour, Paris, France
& Bipin Savani, Nashville, USA*

08.30 Haplo HSCT for SAA: where are we in 2018?

Andrea Bacigalupo, Roma, Italy

09.00 Haplo HSCT for hemoglobinopathies.

Suradej Hongeng, Bangkok, Thailand

09.30 Discussion

09.45 SESSION 10 – EXPERIENCE FROM ASIA

*Chairs: Ephraim Fuchs, Baltimore, USA,
Fatemeh Izadifar-Legrand, Marseille, France
& Claude Lemarié, Marseille, France*

09.45 RIC and ATG based haplo HSCT.

Jong Wook Lee, Seoul, South Korea

10.15 Micro transplant for acute leukemia: a dream?

Huisheng Ai, Beijing, China

10.45 Microtransplant from cord blood source. *Jiong Hu, Shanghai, China*

11.15 Discussion

11.45 *Coffee break & exhibition visit*

12.15 SESSION 11 – POST ALLO TREATMENTS

*Chairs: Jacques-Olivier Bay, Clermont-Ferrand, France
& Sabine Fürst, Marseille, France*

12.15 Treatment of AML relapse after transplant:

what are the tools? *Ivana Gojo, Baltimore, USA*

12.45 Personalized allogeneic immunotherapy for AML.

Raynier Devillier, Marseille, France

13.15 Discussion

13.15 CONCLUDING REMARKS

13.30 *Farewell buffet*

4TH INTERNATIONAL SYMPOSIUM

**ADVANCES IN
ALLOGENEIC
IMMUNOTHERAPY:
WHERE DO WE STAND
IN 2018?**

APRIL
20, 21 & 22
2018

PALAIS DU PHARO
MARSEILLE, FRANCE

ACKNOWLEDGMENTS



GILEAD



MSD

SANOFI

abbvie



BIOGARAN
BIOSIMILAIRES



Bristol-Myers Squibb



CT-RS
Cell Therapies
Research & Services



Jazz Pharmaceuticals
Innovation that performs



janssen



Keocyt



NOVARTIS



Mallinckrodt
Pharmaceuticals



SERVIER

AMGEN



INCYTE



Pierre Fabre



Roche



Pfizer

ALEXION



innate pharma

SANDOZ A Novartis
Division

PUB GILEAD